Dear Colleague,

We are pleased to invite you to a very exciting and intensive accredited educational activity designed specifically for physicians and advanced practitioners involved in the management and treatment of patients with cystic fibrosis. During this half-day course, we will discuss the clinical impact of consequential respiratory pathogens, review long-term treatment data, examine the role of CFTR modulators, and discuss the impact of clinical comorbidities such as nutritional deficits and mental health issues.

We will also interview a patient with cystic fibrosis and then collaborate on strategies to improve patient and family education, ensure smooth transitioning from pediatric to adult care, and develop techniques to help our patients improve their adherence to treatment.

This educational activity is designed to be highly interactive in nature and is limited to a small number of participants. Please plan to register soon. We look forward to seeing you!

Matthias A. Salathe, MD
Program Chairman

Peter J. Mogayzel, Jr., MD, PhD
Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins School of Medicine
Baltimore, MD

Carlos E. Milla, MD
Associate Professor of Pediatrics – Pulmonary Medicine
Director, The Stanford Cystic Fibrosis Center
Associate Director for Translational Research
Center for Excellence in Pulmonary Biology
Stanford University School of Medicine
Palo Alto, CA

Saturday, October 14, 2017 • 8:00 am – 2:30 pm
The Westin Fort Lauderdale • 400 Corporate Drive
Fort Lauderdale, FL

Supported by an independent educational grant from Gilead Sciences Medical Affairs.
LEARNING OBJECTIVES
As a result of attending this activity, participants will be able to:

- Describe the clinical relevance and changing epidemiology of consequential respiratory pathogens.
- Select aerosolized antibiotics by comparing safety, efficacy, and long-term study data, and monitor outcomes for necessary treatment adjustments.
- Describe the evolution of CFTR modulators and decide when they are an appropriate addition to the treatment plan based on patient-specific criteria including mutation analysis.
- Assess the impact of nutrition management, mental health screening, and treatment of comorbid conditions on overall patient outcomes.
- Outline current recommendations for transfer from the pediatric to the adult care setting.
- Appreciate the number and complexity of treatments, and involve patients and/or family in treatment management decisions to improve adherence.

ACCREDITATION
Allcomm, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
Allcomm, Inc. designs this educational activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must complete and submit an activity evaluation form in order to receive a certificate of credit. Certificates will be mailed to participants 4-6 weeks after the activity.
Participants must complete and submit an activity evaluation form in order to receive continuing medical education for physicians.

**LEARNING OBJECTIVES**
As a result of attending this activity, participants will be able to:
- Describe the clinical relevance and changing epidemiology of consequential respiratory pathogens.
- Select aerosolized antibiotics by comparing safety, efficacy, and long-term study data, and monitor outcomes for necessary treatment adjustments.
- Describe the evolution of CFTR modulators and decide when they are an appropriate addition to the treatment plan based on patient specific criteria including mutation analysis.
- Assess the impact of nutrition management, mental health screening, and treatment of comorbid conditions on overall patient outcomes.
- Outline current recommendations for transfer from the pediatric to the adult care setting.
- Appreciate the number and complexity of treatments, and involve patients and/or family in treatment management decisions to improve adherence.

**ACCREDITATION**
Albom, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CREDIT DESIGNATION**
Albom, Inc. designates this educational activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must complete and submit an activity evaluation form in order to receive a certificate of credit. Certificates will be mailed to participants 4-6 weeks after the activity.

**REGISTRATION INFORMATION**
**FIRST NAME** | **LAST NAME** | **DEGREE(S)**
--- | --- | ---
**ADDRESS** | **CITY** | **STATE**
**BILLING ADDRESS** | **ZIP**
**CARD NUMBER** | **EXPIRATION DATE** | **3-4 DIGIT SECURITY CODE**
**PAYMENT INFORMATION**
- Yes
- No
**YEARS IN PRACTICE**
- Pulmonology
- Pediatric Pulmonology
- Critical Care
- Other
**ARE YOU BOARD CERTIFIED?**
- Yes
- No
**ON AVERAGE, HOW MANY PATIENTS WITH CF DO YOU TREAT PER WEEK?**
**HOW DID YOU LEARN ABOUT THIS ACTIVITY?**
- Email
- Brochure or Letter in Mail
- Colleague
**WHAT DO YOU HOPE TO GAIN FROM ATTENDING THIS ACTIVITY?**
**IDENTIFY THE BIGGEST BARRIER TO IMPLEMENTING CHANGES IN YOUR PRACTICE:**
**IF YOU HAVE ANY SPECIAL NEEDS OR DIETARY RESTRICTIONS FOR THIS ACTIVITY, PLEASE SPECIFY:**

**DISCLOSURE STATEMENT**
- It is the policy and practice of ABcomm, Inc. to resolve all potential conflicts of interest prior to activities. This information will be made available to participants at the beginning of the activity.

**REGISTRATION POLICY**
- Your registration fee will be fully refunded if your application is not accepted due to space limitations. In the event that you need to cancel, one-half of your registration fee ($15) will be refunded if written notification is received by October 6, 2017.

**REGISTRATION DEADLINE:** FRIDAY, OCTOBER 6, 2017

**FEE**
The registration fee for Cystic Fibrosis Summit: Current Trends and Future Directions is $30. This fee includes all educational materials, planned group meal functions, and CME certificate. Participants are responsible for their own travel, parking and lodging expenses.

**REGISTRATION DEADLINE: FRIDAY, OCTOBER 6, 2017**

**LOCATION**
The Westin Fort Lauderdale • 400 Corporate Drive
Fort Lauderdale, FL

**DATE AND TIME**
Saturday, October 14, 2017 • 8:00 am–2:30 pm
The Westin Fort Lauderdale • 400 Corporate Drive
Fort Lauderdale, FL

**FAX / SCAN:**
Complete the written application form and email to LValentine@ABcomminc.com or fax to 866-266-9741.

**MAIL:**
Send application form with check payable to Albom, Inc., or credit card information to Albom, Inc., PO Box 7046, Champaign, IL 61826.

**PAYMENT INFORMATION**

**BILLING ADDRESS**

**OTHER INFORMATION**

**WEBSITE**
www.cfsummitfortlauderdale.eventbrite.com

**REGISTRATION FORM**
**ONLINE:** Go to www.cfsummitfortlauderdale.eventbrite.com

**TELEPHONE:** Contact us at (217) 607-1285 during regular business hours.

**FAX / SCAN:** Complete the written application form and email to LValentine@ABcomminc.com or fax to 866-266-9741.

**MAIL:** Send application form with check payable to Albom, Inc., or credit card information to Albom, Inc., PO Box 7046, Champaign, IL 61826.
Dear Colleague,

We are pleased to invite you to a very exciting and intensive accredited educational activity designed specifically for physicians and advanced practitioners involved in the management and treatment of patients with cystic fibrosis. During this half-day course, we will discuss the clinical impact of consequential respiratory pathogens, review long-term treatment data, examine the role of CFTR modulators, and discuss the impact of clinical comorbidities such as nutritional deficits and mental health issues.

We will also interview a patient with cystic fibrosis and then collaborate on strategies to improve patient and family education, ensure smooth transitioning from pediatric to adult care, and develop techniques to help our patients improve their adherence to treatment.

This educational activity is designed to be highly interactive in nature and is limited to a small number of participants. Please plan to register soon. We look forward to seeing you!

Matthias A. Salathe, MD  
Program Chairman

Peter J. Mogayzel, Jr., MD, PhD  
Professor of Pediatrics  
Director, Cystic Fibrosis Center  
Johns Hopkins School of Medicine  
Baltimore, MD

Carlos E. Milla, MD  
Associate Professor of Pediatrics – Pulmonary Medicine  
Director, The Stanford Cystic Fibrosis Center  
Associate Director for Translational Research  
Center for Excellence in Pulmonary Biology  
Stanford University School of Medicine  
Palo Alto, CA

Matthias A. Salathe, MD  
Program Chairman  
Professor of Medicine  
Chief, Division of Pulmonary & Critical Care Medicine  
University of Miami School of Medicine  
Director, Adult Cystic Fibrosis Center  
University of Miami  
Miami, FL

Supported by an independent educational grant from Gilead Sciences Medical Affairs.